During the past decade, Gateway Cardiology, PC conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 7 clinical trials were completed, i.e. on average, 140% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gateway Cardiology, PC" #1 sponsor was "Bristol-Myers Squibb" with 3 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Gilead Sciences" with 2 trials sponsored, "Biotronik SE & Co. KG" with 1 trials sponsored and "Boston Scientific Corporation" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gateway Cardiology, PC" #1 collaborator was "Pfizer" with 3 trials as a collaborator, "Duke Clinical Research Institute" with 2 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "IHF GmbH - Institut für Herzinfarktforschung" with 1 trials as a collaborator and "Qmed Consulting A/S" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Gateway Cardiology, PC" are "Coronary Artery Disease" (2 trials), "Myocardial Infarction" (2 trials), "Acute Coronary Syndrome" (1 trials), "Acute Coronary Syndromes" (1 trials) and "Angina Pectoris" (1 trials). Many other conditions were trialed in "Gateway Cardiology, PC" in a lesser frequency.

Most popular intervention types in "Gateway Cardiology, PC" are "Drug" (8 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Apixaban" (2 trials), "Ranolazine" (2 trials), "99mTechnicium (sestamibi or tetrofosmin)" (1 trials) and "Acetylsalicylic acid" (1 trials). Other intervention names were less common.

The vast majority of trials in "Gateway Cardiology, PC" are 10 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Gateway Cardiology, PC". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Gateway Cardiology, PC, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Gateway Cardiology, PC, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".